Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.

0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 01/10/2023

DEPARTMENT OF BIOCHEMISTRY

Test Parameter Result Unit Bio-Ref Interval

Glucose (Fasting) 84 mg/dl 70-110

Glucose (PP) 162 mg/dl 80 – 120

NB : The blood sugar level depends on various factors like exercise, emotion and drugs including IV
fluids (dextrose solution).

**Please correlate clinically.

 EQUIPMENT USED : ERBA EM 200 FULL AUTO ANALYZ ER

---- END OF REPORT ----

DR. J GHOSH
MBBS,DCH,MD(Pathology)
Consultant Pathologist
Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 01/10/2023

DEPARTMENT OF HAEMATOLOGY

Test Parameter Result Unit Bio-Ref.Interval

Haemoglobin 14.4 gm/dl 13-17

(Non cyanide, SLS Based)

*Please correlate clinically.

 EQUIPMENT USED : ERBA H560 (5 PART) CELL COUNTER.

---- END OF REPORT ----

DR. J GHOSH
MBBS,DCH,MD(Pathology)
Consultant Pathologist.
Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 01/10/2023

DEPARTMENT OF BIOCHEMISTRY

Test Parameter Result Unit Bio-Ref Interval

Creatinine 1.2 mg/dl Male : 0.6-1.4

Female : 0.6-1.2

*Please correlate clinically.

 EQUIPMENT USED : ERBA EM 200 FULL AUTO ANALYZ ER

----END OF REPORT----

DR. J GHOSH
MBBS, DCH, MD (Pathology)
Consultant Pathologist
 Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 01/10/2023

DEPARTMENT OF BIOCHEMISTRY

Test Parameter Result Unit Bio-Ref.Interval

Triglycerides 198 mg/dl < 150

Interpretation :

Remarks Optimal Above Borderline High Very High

Optimal High

 Total Cholesterol in <200 - 200 – 239 >240 -

mg/dl

 Triglyceride in mg/dl <150 - 150 – 199 200 – 499 >500

 LDL Cholesterol in

mg/dl <100 100 – 129 130 – 159 160 – 179 >190

 Non-HDL Cholesterol in

mg/dl
<130 130 - 159 160 – 189 190 - 219 >200
Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 01/10/2023

DEPARTMENT OF BIOCHEMISTRY

Notes :

1. NLA-2014 identifies Non-HDL cholesterol (an indicator of all atherogenicilpoprotens such

as LDL,VLDL, IDL, Lpa, Chylomicron remnants) along with LDL cholesterol as co-
primary target for cholesterol lowering therapy. Note that major risk factors can modify
treatment goals for LDL and Non-HDL.
2. Apolipoprotein B is an optional, secondary lipid target for treatment once LDL and Non-
HDL goals have been achieved.
3. Additional testing for Apolipoprotein B, hs CRP, Lp (a) and LP-PLA 2 should be
considered among patients with moderate risk for ASCVD for risk refinement.

*Please correlate clinically.

 EQUIPMENT USED : ERBA EM 200 FULL AUTO ANALYZER .

---- END OF REPORT ----

DR. J GHOSH
MBBS,DCH,MD(Pathology)
Consultant Pathologist
Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 01/10/2023

DEPARTMENT OF BIOCHEMISTRY

Test Parameter Result Unit Bio-Ref.Interval

ALT(SGPT) 27 IU/L Males - Upto 34

**Please correlate clinically.

 EQUIPMENT USED : ERBA EM 200 FULL AUTO ANALYZER.

----END OF REPORT----

DR. J GHOSH
MBBS, DCH, MD (Pathology)
Consultant Pathologist
Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 02/10/2023

DEPARTMENT OF BIOCHEMISTRY
Test Parameter Result Unit Bio-Ref Interval

HbAlC - Glycocylated Haemoglobin 5.9 % Non-Diabetic : <5.7

Pre-Diabetic : 5.7-6.4
Diabetic : >=6.5

Method : HPLC

Estimated Average Blood Glucose 122.63 mg/dl

1. HbA1c is used for monitoring diabetic control. It reflects the integrated values for glucose over the previous 6-8 weeks.
2. HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association guidelines 2017, for diagnosis of diabetes using a
cut-off point of 6.5%.
3. Trends in HbA1c are a better indicator of diabetic control than a solitary test.
4. Low glycated haemoglobin (below 4%) ina non-diabetic Individual are often associated with systemic
inflammatory diseases, chronic anaemia (especially severe Iron deficiency & haemolytic), chronic
renal failure and liver diseases.
Clinical correlation suggested.
5. To estimate the eAG from the HbA1C value, the following equation is used: eAG(mg/dl) = 28.7*A1c-46.7
6. Interference of Haemoglobinopathies in HbA1c estimation.
A. For HbF > 25% an alternate platform (Fructosamine) 1s recommended for testing of HbA1c.
B. Homozygous hemoglobinopathy is detected, fructosamine is recommended for monitoring diabetic status.
7. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control. Excellent Control-6 to 7
%, Fair to Good Control - 7 to 8 %, Unsatisfactory Control - 8 to 10 % and Poor Control-More than 10%

Primary Sample : EDTA Whole Blood

Instrument Used : D 10 of Bio-Rad

**Please correlate clinically.

---- END OF REPORT ----

DR. J GHOSH
MBBS,DCH,MD(Pathology)
Consultant Pathologist
Patient Name : MR. AJIT KUMAR MONDAL MR No : FTLK.0000000449
Age / Gender : 54 Y / M Test Date : 01/10/2023
Ref by : DR. SHANTHARAM D. MD. Report Date : 02/10/2023

---- END OF REPORT ----

DR. J GHOSH
MBBS,DCH,MD(Pathology)
Consultant Pathologist